Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Towa Pharmaceutical Co., Ltd. (4553.T)
JPY4,115.00
-20.00 (-0.48%)
JP JPX Healthcare Drug Manufacturers - Specialty & Generic
Address
2-11, Shinbashi-cho 571-8580
Osaka, JP
Osaka, JP
CEO
Itsuro Yoshida
Website
towayakuhin.co.jp
IPO
2004-04-05
ISIN JP3623150004
Also trades on
Other OTC · TWAPF (USD)
Tokyo Stock Exchange · 4553.T (JPY)
Description
Towa Pharmaceutical Co., Ltd., along with its subsidiaries, is actively engaged in the entire pharmaceutical lifecycle within Japan, from researching and developing to manufacturing and marketing prescription medications, active pharmaceutical ingredients, and intermediate compounds. The company's extensive product offerings target critical therapeutic areas, including diabetes, digestive and nervous system disorders, and allergic conditions. Furthermore, their portfolio encompasses vitamins, antibiotics, and oncology treatments. With a comprehensive collection of approximately 700 distinct drug products, Towa Pharmaceutical Co., Ltd. was founded in 1951 and is headquartered in Osaka, Japan.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
JPY4,115.00
-20.00 (-0.48%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
136.8K
Beta
-0.11
Float Shares
23.01M
Free Float %
46.7%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.93% | -4.71% | -13.61% | -7.07% | +26.91% | +3.60% | +33.46% | +93.44% | +61.70% | +126.74% | +338.87% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
4,115.00
DCF (Unlevered)
5,209.44
+26.6%
DCF (Levered)
136.51
-96.7%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
67% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 4 | 0 |
| Hold | 2 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
1.99
Grey zone
Piotroski F-Score
6 / 9
Average
MOAT Score
3 / 10
No MOAT
Composite Rating
B
Overall Score
3 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
3 / 5
Medium
ROA Score
4 / 5
High
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+5.4% Q1'26: +5.8% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-72.4% Q1'26: -371.2% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+2.5% ★ Q1'26: +18.2% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+8.4% Q1'26: +5.2% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+3.9% Q1'26: +4.0% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+0.0% Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×4.94× Q1'26: 5.87× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Mar 2015 actual |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 6 Rev. Ana. 6 EPS Ana. |
Mar 2027 6 Rev. Ana. 5 EPS Ana. |
Mar 2028 5 Rev. Ana. 5 EPS Ana. |
Mar 2029 3 Rev. Ana. 3 EPS Ana. |
Mar 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
71.47B
est: 71.40B (+0.1%)
|
82.12B
est: 82.33B (-0.3%)
|
84.95B
est: 86.63B (-1.9%)
|
93.43B
est: 93.76B (-0.4%)
|
105.10B
est: 103.75B (+1.3%)
|
110.38B
est: 111.24B (-0.8%)
|
154.90B
est: 151.77B (+2.1%)
|
165.62B
est: 167.85B (-1.3%)
|
208.86B
est: 211.57B (-1.3%)
|
227.93B
est: 235.95B (-3.4%)
|
259.59B
est: 261.37B (-0.7%)
|
278.05B
274.70B – 279.75B
+6.4% YoY
|
296.81B
288.71B – 302.00B
+6.7% YoY
|
307.39B
299.72B – 318.00B
+3.6% YoY
|
324.70B
322.29B – 327.11B
+5.6% YoY
|
327.50B
318.95B – 336.06B
+0.9% YoY
|
| EBITDA |
16.84B
est: 11.84B (+42.3%)
|
18.46B
est: 13.65B (+35.3%)
|
15.12B
est: 14.36B (+5.3%)
|
19.82B
est: 15.54B (+27.5%)
|
24.62B
est: 17.20B (+43.2%)
|
24.46B
est: 18.44B (+32.6%)
|
30.35B
est: 25.16B (+20.6%)
|
29.49B
est: 27.83B (+6.0%)
|
24.92B
est: 35.07B (-28.9%)
|
35.54B
est: 42.61B (-16.6%)
|
43.34B
est: 47.20B (-8.2%)
|
50.21B
49.61B – 50.52B
+6.4% YoY
|
53.60B
52.14B – 54.54B
+6.7% YoY
|
55.51B
54.13B – 57.43B
+3.6% YoY
|
58.64B
58.20B – 59.07B
+5.6% YoY
|
59.14B
57.60B – 60.69B
+0.9% YoY
|
| EBIT |
11.12B
est: 6.38B (+74.3%)
|
11.13B
est: 7.35B (+51.4%)
|
7.14B
est: 7.74B (-7.7%)
|
11.64B
est: 8.38B (+39.0%)
|
16.28B
est: 9.27B (+75.7%)
|
16.17B
est: 9.94B (+62.7%)
|
19.93B
est: 13.56B (+47.0%)
|
18.54B
est: 14.99B (+23.6%)
|
5.52B
est: 18.90B (-70.8%)
|
17.65B
est: 20.56B (-14.2%)
|
23.24B
est: 22.78B (+2.0%)
|
24.23B
23.94B – 24.38B
+6.4% YoY
|
25.87B
25.16B – 26.32B
+6.7% YoY
|
26.79B
26.12B – 27.72B
+3.6% YoY
|
28.30B
28.09B – 28.51B
+5.6% YoY
|
28.54B
27.80B – 29.29B
+0.9% YoY
|
| Net Income |
11.12B
est: 9.39B (+18.4%)
|
7.68B
est: 8.31B (-7.6%)
|
5.58B
est: 4.17B (+33.7%)
|
6.50B
est: 8.14B (-20.2%)
|
13.48B
est: 9.72B (+38.6%)
|
14.50B
est: 12.05B (+20.3%)
|
13.96B
est: 12.02B (+16.1%)
|
15.91B
est: 16.96B (-6.2%)
|
2.20B
est: 5.76B (-61.8%)
|
16.17B
est: 16.92B (-4.4%)
|
18.99B
est: 16.00B (+18.6%)
|
20.42B
15.79B – 22.27B
+27.6% YoY
|
19.91B
16.52B – 22.28B
-2.5% YoY
|
21.62B
17.80B – 24.60B
+8.6% YoY
|
21.74B
19.89B – 25.25B
+0.6% YoY
|
24.81B
23.96B – 25.65B
+14.1% YoY
|
| SGA |
11.28B
est: 17.32B (-34.9%)
|
12.26B
est: 19.98B (-38.6%)
|
22.55B
est: 21.02B (+7.3%)
|
23.68B
est: 22.75B (+4.1%)
|
24.20B
est: 25.17B (-3.9%)
|
25.91B
est: 26.99B (-4.0%)
|
34.88B
est: 36.83B (-5.3%)
|
40.16B
est: 40.73B (-1.4%)
|
51.93B
est: 51.34B (+1.2%)
|
50.49B
est: 56.78B (-11.1%)
|
55.27B
est: 62.90B (-12.1%)
|
66.91B
66.11B – 67.32B
+6.4% YoY
|
71.43B
69.48B – 72.68B
+6.7% YoY
|
73.97B
72.13B – 76.53B
+3.6% YoY
|
78.14B
77.56B – 78.72B
+5.6% YoY
|
78.81B
76.76B – 80.88B
+0.9% YoY
|
| EPS |
218.06
est: 190.72 (+14.3%)
|
154.18
est: 168.87 (-8.7%)
|
113.31
est: 84.75 (+33.7%)
|
131.99
est: 165.28 (-20.1%)
|
273.83
est: 197.52 (+38.6%)
|
294.72
est: 244.87 (+20.4%)
|
283.62
est: 244.13 (+16.2%)
|
323.35
est: 344.60 (-6.2%)
|
44.72
est: 117.51 (-61.9%)
|
328.58
est: 343.72 (-4.4%)
|
385.70
est: 318.31 (+21.2%)
|
414.78
320.76 – 452.33
+30.3% YoY
|
412.39
335.55 – 452.62
-0.6% YoY
|
439.22
361.50 – 499.75
+6.5% YoY
|
474.40
404.00 – 512.93
+8.0% YoY
|
503.90
486.79 – 521.03
+6.2% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | B | 3/5 | 3/5 | 3/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-14 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-13 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-12 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-11 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-08 | A | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 4/5 | 4/5 |
| 2026-05-07 | A | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 4/5 | 4/5 |
| 2026-05-01 | A | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-30 | A | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-28 | A | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-27 | A | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-24 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-23 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-22 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-21 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-20 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-17 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-16 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
17.09B
OE per share TTM
347.16
Owner's Yield
9.18%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
63.3%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 84 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | WisdomTree Japan SmallCap Dividend Fund DFJ | 0.12% | 459.2K | 0.58% |
| 2 | Dimensional - International Small Cap Value ETF DISV | 0.08% | 3.56M | 0.42% |
| 3 | iShares Ageing Population UCITS ETF AGED.L | 0.07% | 609.2K | 0.40% |
| 4 | iShares MSCI Japan Small Cap UCITS ETF IDJP.L | 0.05% | 280.0K | 0.58% |
| 5 | iShares MSCI Japan Small-Cap ETF SCJ | 0.05% | 119.9K | 0.50% |
| 6 | FlexShares Morningstar Developed Markets ex-US Factor Tilt Index Fund TLTD | 0.04% | 240.7K | 0.41% |
| 7 | Avantis International Small Cap Value ETF AVDV | 0.04% | 6.72M | 0.36% |
| 8 | WisdomTree Japan Equity UCITS ETF - GBP Hedged DXJP.L | 0.03% | 378.9K | 0.45% |
| 9 | WisdomTree Japan Equity UCITS ETF - USD Hedged Acc DXJA.L | 0.03% | 283.3K | 0.48% |
| 10 | WisdomTree Japan Equity UCITS ETF - CHF Hedged Acc DXJD.SW | 0.03% | 349.7K | 0.45% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
5.04M
Shares Outstanding
49.23M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Itsuro Yoshida | President & Representative Director | 113M | male |
| Masao Tanaka | Director | — | male |
| Naomichi Hashizume | Human Resources Division Chief | — | — |
| Norikazu Inoue | Executive Officer & GM of Administration Division | — | male |
| Osamu Uchikawa | Executive MD & Director | — | male |
| Shigeki Fujita | Operating Officer & GM of Human Resource Development Center | — | — |
| Shiro Hatagami | Executive Officer & GM of Accounting and Finance Division | — | — |
| Takahiko Taniguchi | Senior Executive Officer & Head of Quality Assurance Division | — | — |
| Takeshi Sugiura | Executive Officer | — | — |
| Tetsuro Tabata | Senior Executive Officer & GM of Production Division | — | — |
| Yasuyuki Oishi | Executive Officer | — | — |
| Yutaka Okuda | Senior Exe. Officer & Div Manager of R&D Div and Unit Manager of Innovative Tech Research Unit | — | — |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4553.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
